Clinical Trials - Topline data from the PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis (RRMS) is expected in Q4 2025[1]. - A global Phase 2 clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) is set to begin in Q4 2025[1]. - The PIPE-791 Phase 1b trial for chronic pain is expected to report topline data in the first half of 2026[3]. - The Company has deferred the initiation of PIPE-791 PrMS and CTX-343 clinical development efforts[5]. Financial Performance - Cash, cash equivalents, and marketable securities totaled $182.4 million as of September 30, 2025, with a projected cash runway extending through 2028[10]. - Research and development expenses increased by 13% to $11.0 million compared to Q3 2024, driven by higher clinical development costs[10]. - General and administrative expenses rose by 21% to $3.9 million compared to Q3 2024, primarily due to increased stock-based compensation[10]. - The net loss for Q3 2025 was $12.8 million, compared to a net loss of $10.3 million in the same quarter of the previous year[10]. - The total operating expenses for Q3 2025 were $14.9 million, up from $13.0 million in Q3 2024[10]. - The Company reported a comprehensive loss of $12.7 million for Q3 2025, compared to $9.6 million in Q3 2024[10].
Contineum Therapeutics, Inc.(CTNM) - 2025 Q3 - Quarterly Results